A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a
Abstract
In a 12-month follow-up study, we evaluated 27 patients (18 F and 9 M) with relapsing-remitting (RR) multiple sclerosis (MS), who had started treatment with interferon beta-1a (IFNbeta-1a) (Avonex), 30 microg i.m. once weekly, 6-18 months (median 10 months) before study entry. Quality of life (QOL), disability, independence, cognitive performances, symptoms of depression and anxiety, and fatigue were assessed at baseline, 6 months and 12 months. The frequency and severity of the side effects of treatment, at hours 0-12, 13-48 and 49-168 after the injection, were self-reported weekly in a structured questionnaire. QOL did not change significantly during the follow-up. The percentage of patients who reported side effects after the injection of IFNbeta-1a remained constant during the 52 weeks. The mean number of side effects increased significantly from the 6th to the 12th month. The general linear model analysis of variance disclosed significant changes over time for almost all side effects, but we did not find any correlation between QOL and number of side effects. In conclusion, 1-year treatment with IFNbeta-1a did not significantly change patient's QOL. Disability progression correlated with patient's QOL. Side effects, which were mild, did not diminish over time, did not induce treatment discontinuation and did not interfere with QOL.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
HRQOL has gained increasing status as a metric of treatment effectiveness.
“although HRQOL has gained increasing status as a metric of treatment effectiveness.11–14,20”
From MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial (2010) · cites this paper as [13]
Many disease-modifying drug regimens appear to produce modest or no improvements in HRQOL or even negative changes.
“many disease-modifying drug regimens appear to produce modest or no improvements in HRQOL7,11–14 or even negative changes.15”
From MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial (2010) · cites this paper as [13]
Disease-modifying treatments do not necessarily have beneficial impact upon HRQOL or coping responses.
“Disease-modifying treatments do not necessarily have beneficial impact upon HRQOL or coping responses.7,11–13”
From MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial (2010) · cites this paper as [13]
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011 · see citing works
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455 · see citing works
SF-36 health survey: Manual and interpretation guide
Ware, J. (2003) · Medical Entomology and Zoology · Cited by 11,424 · see citing works
Development of a Rating Scale for Primary Depressive Illness
Hamilton, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410 · see citing works
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384 · see citing works
Krupp, L. B. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460115022 · Cited by 6,172 · see citing works
Defining the clinical course of multiple sclerosis
LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,687 · see citing works
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. Μ., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,446 · see citing works
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,144 · see citing works
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085 · see citing works
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,964 · see citing works
Girard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,197 · see citing works
A health-related quality of life measure for multiple sclerosis
Vickrey, B. G., Hays, R. D., Harooni, R., Myers, L. W., & Ellison, G. W. (1995) · Quality of Life Research · doi:10.1007/bf02260859 · Cited by 1,132 · see citing works
Interferon beta‐lb in the treatment of multiple sclerosis
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) · Neurology · doi:10.1212/wnl.45.7.1277 · Cited by 971 · see citing works
Kappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936 · see citing works
Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument
Cella, D. F., Dineen, K. K., Arnason, B. G. W., Reder, A. T., Webster, K., Karabatsos, G., Chang, C., Lloyd, S. R., Mo, F., Stewart, J., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.129 · Cited by 414 · see citing works
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
Cohen, J. A., Cutter, G., Fischer, J. S., Goodman, A. D., Heidenreich, F., Kooijmans, M., Sandrock, A., Rudick, R. A., Simon, J. H., Simonian, N. A., et al. (2002) · Neurology · doi:10.1212/wnl.59.5.679 · Cited by 401 · see citing works
Walther, E. U., & Hohlfeld, R. (1999) · Neurology · doi:10.1212/wnl.53.8.1622 · Cited by 303 · see citing works
Management of patients receiving interferon beta-1b for multiple sclerosis
LUBLIN, F. D., Whitaker, J. N., Eidelman, B. H., Miller, A., Arnason, B. G. W., & BURKS, J. S. (1996) · Neurology · doi:10.1212/wnl.46.1.12 · Cited by 169 · see citing works
Janardhan, V., & Bakshi, R. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1485 · Cited by 137 · see citing works
Paty, D. W., & Li, D. K. (2001) · PubMed · Cited by 130 · see citing works
Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-la
Mohr, D. C., Likosky, W., Boudewyn, A. C., Marietta, P., Dwyer, P., Wende, J. V. D., & Goodkin, D. E. (1998) · Multiple Sclerosis Journal · doi:10.1177/135245859800400605 · Cited by 75 · see citing works
Treatment with Interferon Beta-1b Improves Quality of Life in Multiple Sclerosis
Rice, G. P. A., Oger, J., Duquette, P., Francis, G., Bélanger, M., Laplante, S., & Grenier, J.-F. (1999) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710000038x · Cited by 74 · see citing works
Quality of life in multiple sclerosis: influence of interferon-β1a (Avonex®) treatment
Vermersch, P., de Seze, J., Delisse, B., Lemaire, S., & Stojkovic, T. (2002) · Multiple Sclerosis Journal · doi:10.1191/1352458502ms826oa · Cited by 74 · see citing works
Interferon-β1b in the treatment of secondary progressive MS
Freeman, J. A., Thompson, A. J., Fitzpatrick, R. M., Hutchinson, M., Miltenburger, C., Beckmann, K., Dahlke, F., Kappos, L., Polman, C. H., Pozzilli, C., et al. (2001) · Neurology · doi:10.1212/wnl.57.10.1870 · Cited by 71 · see citing works
The Quality-of-Life Effects of Interferon Beta-1b in Multiple Sclerosis
Schwartz, C. E. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550240029009 · Cited by 67 · see citing works
Quality of life during the first 6 months of interferon-b treatment in patients with MS
Arnoldus, J. H. A., Killestein, J., Pfennings, L. E. M. A., Jelles, B., Uitdehaag, B. M. J., & Polman, C. H. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600508 · Cited by 62 · see citing works
Gottberg, K., Gardulf, A., & Fredrikson, S. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600510 · Cited by 55 · see citing works
Quality of life in multiple sclerosis
Rothwell, P. M. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.4.433 · Cited by 41 · see citing works
Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-1a
Mohr, D. C., Likosky, W., Boudewyn, A. C., Marietta, P., Dwyer, P., Wende, J. V. D., & Goodkin, D. E. (1998) · Multiple Sclerosis Journal · doi:10.1191/135245898678845160 · Cited by 38 · see citing works
Uncinate seizures and tumors, a myth reexamined
Howe, J. G., & Gibson, J. D. (1982) · Annals of Neurology · doi:10.1002/ana.410120238 · Cited by 34 · see citing works
Management of cancer patients receiving interferon alfa-2a
Gauci, L. (1987) · International Journal of Cancer · doi:10.1002/ijc.2910390706 · Cited by 16 · see citing works
Principles of treatments in multiple sclerosis
Hawkins, C., & Wolinsky, J. S. (2000) · Butterworth-Heinemann eBooks · Cited by 16 · see citing works
Pozzilli, C., & Koudriavtseva, T. (1997) · PubMed · Cited by 6 · see citing works
Flagged first, then by citations
1 of the 36 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798 · see citing works
Benedict, R. H. B., Wahlig, E., Bakshi, R., Fishman, I., Munschauer, F., Zivadinov, R., & Weinstock-Guttman, B. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.12.009 · Cited by 528 · see citing works
Self-citationMitchell, A. J., Benito‐León, J., González, J.-M. M., & Navarro, J. R. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70166-6 · Cited by 518 · see citing works
MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial
Grossman, P., Kappos, L., Gensicke, H., D'Souza, M., Mohr, D. C., Penner, I. K., & Steiner, C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f4d80d · Cited by 419 · see citing works
Molecular Trojan horses for blood–brain barrier drug delivery
Pardridge, W. M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.06.001 · Cited by 259 · see citing works
Health‐related quality of life in multiple sclerosis: effects of natalizumab
Rudick, R. A., Miller, D., Hass, S., Hutchinson, M., Calabresi, P. A., Confavreux, C., Galetta, S. L., Giovannoni, G., Havrdova, E., Kappos, L., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21163 · Cited by 195 · see citing works
Predictors of quality of life among multiple sclerosis patients: a comprehensive analysis
Yamout, B., Issa, Z. A., Herlopian, A., Bejjani, M. E., Khalifa, A., Ghadieh, A. S., & Habib, R. (2013) · European Journal of Neurology · doi:10.1111/ene.12046 · Cited by 135 · see citing works
Mowry, E. M., Loguidice, M. J., Daniels, A. B., Jacobs, D. A., Markowitz, C., Galetta, S. L., Nano-Schiavi, M. L., Cutter, G., Maguire, M. G., & Balcer, L. J. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.165449 · Cited by 132 · see citing works
Giovannoni, G., Southam, E., & Waubant, E. L. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458511433302 · Cited by 128 · see citing works
Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis
Landmeyer, N. C., Bürkner, P., Wiendl, H., Ruck, T., Hartung, H., Holling, H., Meuth, S. G., & Johnen, A. (2020) · Neurology · doi:10.1212/wnl.0000000000009522 · Cited by 125 · see citing works
Pilot trial of low‐dose naltrexone and quality of life in multiple sclerosis
Cree, B., Kornyeyeva, E., & Goodin, D. S. (2010) · Annals of Neurology · doi:10.1002/ana.22006 · Cited by 125 · see citing works
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · Neurotherapeutics · doi:10.1007/bf03206638 · Cited by 128 · see citing works
Cognitive Dysfunctions and Assessments in Multiple Sclerosis
Oreja-Guevara, C., Blanco, T. A., Ruiz, L. B., Pérez, M. Á. H., Meca-Lallana, V., & Ramió-Torrentá, L. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00581 · Cited by 102 · see citing works
Quality of life and impairment in patients with multiple sclerosis
Isaksson, A.-K. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.029660 · Cited by 111 · see citing works
Health-Related Quality of Life in Multiple Sclerosis
Rudick, R. A., & Miller, D. M. (2008) · CNS Drugs · doi:10.2165/00023210-200822100-00004 · Cited by 97 · see citing works
Psychiatric side effects of interferon-β in multiple sclerosis
Goëb, J.-L., EVEN, C., Nicolas, G., Gohier, B., Dubas, F., & Garré, J.-B. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2005.09.013 · Cited by 95 · see citing works
Jongen, P. J. (2017) · CNS Drugs · doi:10.1007/s40263-017-0444-x · Cited by 82 · see citing works
Quality of life in 1000 patients with early relapsing–remitting multiple sclerosis
Putzki, N., Fischer, J., Gottwald, K., Reifschneider, G., Ries, S., Siever, A., Hoffmann, F., Käfferlein, W., Kausch, U., Liedtke, M., et al. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02572.x · Cited by 80 · see citing works
Nourbakhsh, B., Julian, L. J., & Waubant, E. L. (2016) · European Journal of Neurology · doi:10.1111/ene.13102 · Cited by 79 · see citing works
Influence of Interferon beta treatment on quality of life in multiple sclerosis patients
Simone, I. L., Ceccarelli, A., Tortorella, C., Bellacosa, A., Pellegrini, F., Plasmati, I., De Caro, M. F., Lopez, M., Girolamo, F., & Livrea, P. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-96 · Cited by 67 · see citing works
Treatment of fatigue in multiple sclerosis: A systematic review of the literature
Lee, D., Newell, R., Ziegler, L. E., & Topping, A. E. (2008) · International Journal of Nursing Practice · doi:10.1111/j.1440-172x.2008.00670.x · Cited by 66 · see citing works
Kappos, L., Gold, R., Arnold, D. L., Bar‐Or, A., Giovannoni, G., Selmaj, K. W., Sarda, S. P., Agarwal, S., Zhang, A., Sheikh, S. I., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513507817 · Cited by 65 · see citing works
Quality of Life in Multiple Sclerosis: Determinants, Measurement, and Use in Clinical Practice
Miller, D. M., & Allen, R. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0132-4 · Cited by 60 · see citing works
Multiple sclerosis associated fatigue during natalizumab treatment
Putzki, N., Yaldizli, Ö., Tettenborn, B., & Diener, H. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.06.004 · Cited by 59 · see citing works
Health-related quality of life in secondary progressive multiple sclerosis
Beiske, A. G., Næss, H., Aarseth, J. H., Andersen, O., Elovaara, I., Färkkilä, M. A., Hansen, H. J., Mellgren, S. I., Sandberg‐Wollheim, M., Sørensen, P. S., et al. (2007) · Multiple Sclerosis Journal · doi:10.1177/13524585070130030101 · Cited by 57 · see citing works
Patti, F., Amato, M. P., Trojano, M., Bastianello, S., Tola, M. R., Picconi, O., Cilia, S., Cottone, S., Centonze, D., Gasperini, C., et al. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511401943 · Cited by 51 · see citing works
Miller, D. M., Rudick, R. A., & Hutchinson, M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dbb884 · Cited by 47 · see citing works
Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment
Lily, O., McFadden, E., Hensor, E. M. A., Johnson, M. H., & Ford, H. L. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458506070946 · Cited by 47 · see citing works
Mohr, D. C., Burke, H., Beckner, V., & Merluzzi, N. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1150oa · Cited by 46 · see citing works
Enhancement of drug permeability across blood brain barrier using nanoparticles in meningitis
Nair, K. G. S., Velmurugan, R., & Kumar, S. S. (2018) · Inflammopharmacology · doi:10.1007/s10787-018-0468-y · Cited by 44 · see citing works
Maggio, M. G., Cuzzola, M. F., Latella, D., Impellizzeri, F., Todaro, A., Rao, G., Manuli, A., & Calabrò, R. S. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102560 · Cited by 43 · see citing works
Pozzilli, C., Schweikert, B., Ecari, U., Oentrich, W., & Bugge, J. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6492-8 · Cited by 32 · see citing works
The Functional composite and quality of Life in Avonex-treated Relapsing multiple sclerosis patients (FLAIR) study group, Jongen, P. J., Sindic, C., Carton, H., Zwanikken, C., Lemmens, W. A. J. G., & Borm, G. F. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5378-x · Cited by 32 · see citing works
Barriers and Facilitators Related to Rehabilitation Stays in Multiple Sclerosis
Helland, C. B., Holmøy, T., & Gulbrandsen, P. (2014) · International Journal of MS Care · doi:10.7224/1537-2073.2014-007 · Cited by 31 · see citing works
Nadjar, Y., Coutelas, E., Prouteau, P., Panzer, F., Paquet, D., Saint-Val, C., & Créange, A. (2011) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2010.12.013 · Cited by 30 · see citing works
Impact and characteristics of quality of life in Japanese patients with multiple sclerosis
Kikuchi, H., Mifune, N., Niino, M., Ohbu, S., Kira, J., Kohriyama, T., Ota, K., Tanaka, M., Ochi, H., Nakane, S., et al. (2010) · Quality of Life Research · doi:10.1007/s11136-010-9725-2 · Cited by 29 · see citing works
Quality of life in multiple sclerosis: Effects of current treatment options
Kargiotis, O., Paschali, A. N., Messinis, L., & Papathanasopoulos, P. (2010) · International Review of Psychiatry · doi:10.3109/09540261003589521 · Cited by 27 · see citing works
Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a
Guo, S., Bozkaya, D., Ward, A., O’Brien, J. A., Ishak, K. J., Bennett, R., Al‐Sabbagh, A., & Meletiche, D. M. (2009) · PharmacoEconomics · doi:10.2165/00019053-200927010-00005 · Cited by 26 · see citing works
Dymecka, J., & Bidzan, M. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15122678 · Cited by 25 · see citing works
Depression Levels and Interferon Treatment in People with Multiple Sclerosis
Kim, S., Foley, F. W., Picone, M. A., Halper, J., & Zemon, V. M. (2012) · International Journal of MS Care · doi:10.7224/1537-2073-14.1.10 · Cited by 22 · see citing works
Miller, D., Weinstock‐Guttman, B., BOURDETTE, D. N., You, X., Foulds, P., & Rudick, R. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458510397221 · Cited by 22 · see citing works
Patten, S. B., Williams, J., & Metz, L. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458507082942 · Cited by 20 · see citing works
Impact of a Seizure Disorder Disease Management Program on Patient-Reported Quality of Life
Gunter, M. J., Brixner, D. L., Worley, A. V., Carter, S., & Gregory, C. (2004) · Disease Management · doi:10.1089/dis.2004.7.333 · Cited by 18 · see citing works
Lebensqualität bei Multipler Sklerose
Pöllmann, W., Busch, C., & Voltz, R. (2004) · Der Nervenarzt · doi:10.1007/s00115-004-1790-8 · Cited by 17 · see citing works
Jongen, P. J., Sindic, C., Sanders, E. A. C. M., Hawkins, S. A., Linssen, W. H. J. P., van Munster, E., Frequin, S. T. F. M., Borm, G. F., & and the Functional composite and quality of Life in Avonex-treated Relapsing multiple sclerosis patients (FLAIR) Study Group (2011) · PLoS ONE · doi:10.1371/journal.pone.0026568 · Cited by 16 · see citing works
Therapeutic effect of A vonex, R ebif and B etaferon on quality of life in multiple sclerosis
Mokhber, N., Azarpazhooh, A., Orouji, E., Khorram, B., Gharavi, M. M., Kakhi, S., Khallaghi, H., & Azarpazhooh, M. R. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12308 · Cited by 15 · see citing works
Health-related quality of life in Iranian patients with multiple sclerosis: a cross-cultural study.
Pakpour, A. H., Yekaninejad, M. S., Mohammadi, N. K., Mølsted, S., Zarei, F., Patti, F., & Harrison, A. P. (2009) · PubMed · Cited by 15 · see citing works
Exacerbation history is associated with medication and appointment adherence in MS
Hancock, L. M., Bruce, J. M., & LYNCH, S. G. (2011) · Journal of Behavioral Medicine · doi:10.1007/s10865-011-9316-x · Cited by 14 · see citing works
Relationship between Ultrasonic Marker of Fetal Lung Maturity and Lamellar Body Count
Keikhaie, K. R., Kahkhaie, K. R., Mohammadi, N., Amjadi, N., Forg, A. A., & Ramazani, A. A. (2017) · Journal of the National Medical Association · doi:10.1016/j.jnma.2017.01.012 · Cited by 13 · see citing works
Impact of multiple sclerosis on quality of life: Comparison with systemic lupus erythematosus
Contentti, E. C., Genco, N. D., Hryb, J. P., Caspi, M., Chiganer, E., Pace, J. L. D., López, P. A., Lessa, C. F., Caride, A., & Perassolo, M. B. (2017) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2017.10.032 · Cited by 13 · see citing works
Cerghet, M., Dobie, E., Lafata, J. E., Schultz, L. R., Elias, S. B., Pladevall, M., & Reuther, J. (2010) · International Journal of MS Care · doi:10.7224/1537-2073-12.2.51 · Cited by 13 · see citing works
Pakdaman, H., Harandi, A. A., Gharagozli, K., Abbasi, M., Tabasi, A., Ashrafi, F., Ghaffarpor, M., Sharifi, S., Kasmaei, H. D., Assarzadegan, F., et al. (2016) · International Journal of Neuroscience · doi:10.1080/00207454.2016.1198793 · Cited by 10 · see citing works
Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis
Tumani, H., & Uttner, I. (2007) · Journal of Neurology · doi:10.1007/s00415-007-2016-3 · Cited by 9 · see citing works
Patti, F., Pappalardo, A., Montanari, E., Pesci, I., Barletta, V. T., & Pozzilli, C. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.12.006 · Cited by 8 · see citing works
Seifi, K., & Moghaddam, H. E. (2017) · Journal of the National Medical Association · doi:10.1016/j.jnma.2017.01.010 · Cited by 8 · see citing works
Antiinfective Agents Affecting Cognition: A Review
Khalifa, A. E. (2007) · Journal of Chemotherapy · doi:10.1179/joc.2007.19.6.620 · Cited by 8 · see citing works
Lebensqualität bei Multipler Sklerose: Messinstrumente, Bedeutung, Probleme und Perspektiven
Pöllmann, W., Busch, C., & Voltz, R. (2005) · Der Nervenarzt · Cited by 7 · see citing works
Le, H. H., Stocks, S. J., & Ait-Tihyaty, M. (2024) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2024.105846 · Cited by 5 · see citing works
Sleep and Quality of Life in Multiple Sclerosis
de Vries, J. M. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-343-5_22 · Cited by 5 · see citing works
Gil-Ad, I., Amit, B. H., Hayardeni, L., Tarasenko, I., Taler, M., Gueta, R. U., & Weizman, A. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0387-3 · Cited by 5 · see citing works
Jongen, P. J., Sindic, C., & Zwanikken, C. (2010) · Cited by 5 · see citing works
Health-Related Quality of Life in MS: Issues and Interventions
Warren, S., Turpin, K. V. L., & Warren, K. G. (2009) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100008003 · Cited by 5 · see citing works
An Overview of Various Approaches for Brain Targeted Drug Delivery System
Parthiban, R., M., M., Bhupathyraaj, M., Sridhar, S., Shareef, J., Thomas, S., & Janakiraman, A. K. (2024) · International journal of Nutrition Pharmacology Neurological Diseases · doi:10.4103/ijnpnd.ijnpnd_72_23 · Cited by 2 · see citing works
Foley, J. F., Barnes, C. J., & Nair, K. V. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.s1.s16 · Cited by 3 · see citing works
Painful symptoms and quality of life in multiple sclerosis
Niino, M. (2008) · Cited by 3 · see citing works
Comparative impact of mental and cardiovascular comorbidities on adverse outcomes in people with MS
France‐Ratcliffe, M., Harrison, S. L., Verma, L. A., Abdul‐Rahim, A. H., McCallum, L., McDowell, G., Young, C. A., & Buckley, B. J. R. (2026) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2026.126007 · Cited by 2 · see citing works
Baldauf, E., Gross, M., Fleury, M., Gentin, M., Souvignet, V., & Warter, J. (2005) · Revue Neurologique · doi:10.1016/s0035-3787(05)85193-8 · Cited by 1 · see citing works
Stopeleire, C. D., Adida, M., Labrune, N., & Lançon, C. (2005) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2005.06.001 · Cited by 1 · see citing works
Management and Care – The Changing Landscape of Multiple Sclerosis
Lee, C., Wong, P., Editor, & Senior Editor, T. B. (2008) · European Neurological Review · doi:10.17925/enr.2008.03.02.77 · Cited by 1 · see citing works
Disability in people with multiple sclerosis with focus on fatigue
Johansson, S. (2008) · Figshare
Loftis, J. M., & Hauser, P. (2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.680
Guillermo, H. P. (2014) · Journal of Neurology & Neurophysiology · doi:10.4172/2155-9562.1000193
SIDE EFFECTS OF β-INTERFERON: A COMPARATIVE STUDY AMONG AVONEX, BETASERON AND REBIF
Etemadifar, M., Basiri, K., & Tavakoli, N. (2005) · Iranian journal of pharmaceutical sciences
Living with pediatric multiple sclerosis: patient well-being
Im-Wang, S., Milazzo, M. C., & Mowry, E. M. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511974373.015
Pediatric MS Course and Treatment
Chabas, D., & Waubant, E. L. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511974373.008
Lariviere, M. (2011) · Dominican Scholar (Dominican University of California)
Kraft, G. H., Brown, T. R., & Johnson, S. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0884-4.10052-7
Immunopathology and Pathogenesis
Zettl, U. K., & Patejdl, R. (2023) · Springer eBooks · doi:10.1007/978-3-031-13498-2_4
Terrill, E. (2007) · eScholarship@UMassChan · doi:10.13028/rkhy-2p65
Multiple sclerosis, disease-modifying treatments and behavioral change
Feinstein, A. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511543760.012
- Authors
- Zivadinov, R., Zorzon, M., Tommasi, M. A., Nasuelli, D., Bernardi, M., Monti-Bragadin, L., & Cazzato, G.
- Affiliations
- University of Trieste (IT)
- Corresponding author
- Zorzon, Marino
- ORCID
- Zivadinov, Robert
- Venue
- Journal of the Neurological Sciences
- Publisher
- Elsevier BV
- Published
- 2003-12
- Volume
- 216
- Issue
- 1
- Pages
- 113-118
- ISSN
- 0022-510X (ISSN-L)
- OpenAlex
- W2043447672
- Cited by
- 81
- References
- 36
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 1 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 2 · 2015: 1 · 2014: 5 · 2013: 3 · 2012: 3
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of the Neurological Sciences (publishedVersion)
- PubMed (publishedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Keywords
- multiple sclerosis, interferon beta-1a, Avonex, quality of life, treatment side effects, relapsing-remitting multiple sclerosis, disability progression, fatigue, depression, anxiety, cognitive performance, medication adherence
- MeSH terms
- Interferon beta-1a, Activities of Daily Living, Adolescent, Adult, Analysis of Variance, Anxiety, Cognition, Depression, Disability Evaluation, Fatigue, Female, Humans, Longitudinal Studies, Male, Middle Aged, Multiple Sclerosis, Quality of Life, Surveys and Questionnaires, Linear Models, Interferon-beta, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
